Welcome to Xbrane’s Capital Markets Day, including a unique visit to the new research lab, on September 22, 2022
Other Corporate Information
Stockholm, Sweden – Xbrane (Nasdaq: XBRANE), Xbrane Biopharma AB invites analysts, investors and the media to its Capital Markets Day on September 22, 2022
The Capital Markets Day will be held in the Nils Ringertz hall, Biomedicum, floor 3, Solnavägen 9, Solna, starting at 2 pm and will also be broadcast digitally.
The program includes an update of Xbrane's long-term strategy, product portfolio, platform technology and an in-depth look at the imminent launch of Xlucane in Europe. Presentations will be made by Anders Tullgren, Chairman of the Board, Martin Åmark, CEO, David Vikström, Head of R&D, and Bryan Kim, Executive Vice President Global Specialty Pharmaceuticals, STADA Arzneimittel AG.
The program will also include a tour of Xbrane's new research lab at Campus Solna for those interested.
Please register your personal participation at: IR@xbrane.com and digital participation by following the link:
Participants are welcome to ask questions at IR@xbrane.com or directly during the event.
Recordings of the presentations and presentation material will be available on the company's website, www.xbrane.com, the day after the event.